Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

Completed · Phase 2

Conditions studied: Tuberous Sclerosis, Lymphangioleiomyomatosis

In brief

The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.

Key facts

Study ID

NCT00457808

Run by

Children's Hospital Medical Center, Cincinnati

People needed

25

Starts

2002-12-01

Expected to finish

2006-03-01

Last updated by the study team

2007-04-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with angiomyolipomas and have either Tuberous Sclerosis complex or Lymphangioleiomyomatosis
• Between the gaes of 18 and 65 years
• Competency to voluntarily consent
• Clinically definite diagnosis of tuberous sclerosis or S-LAM
• Adequate contraception
• At least one angiomyolipoma of 1 cm or greater in largest diameter

You may not qualify if…

• Use of continuous supplemental oxygen
• Concurrent infection
• Recent surgery
• Ongoing or planned pregnancy
• Lactation
• Use of an investigational drug within the last 30 days of study entrance

Where it is running

• Cincinnati Childrens Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.